Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Interest & Investment Income (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Interest & Investment Income for 4 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 31.48% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.5 million, a 6.24% decrease, with the full-year FY2025 number at $18.5 million, down 6.24% from a year prior.
  • Interest & Investment Income was $4.1 million for Q4 2025 at Day One Biopharmaceuticals, down from $4.6 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $6.1 million in Q4 2024 to a low of $2000.0 in Q1 2022.
  • A 4-year average of $3.8 million and a median of $4.3 million in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 173200.0% in 2023, then plummeted 31.48% in 2025.
  • Day One Biopharmaceuticals' Interest & Investment Income stood at $2.7 million in 2022, then soared by 88.87% to $5.0 million in 2023, then grew by 20.46% to $6.1 million in 2024, then tumbled by 31.48% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Interest & Investment Income are $4.1 million (Q4 2025), $4.6 million (Q3 2025), and $4.7 million (Q2 2025).